# A Triple Combination Therapy Study of Boceprevir, Pegasys and Copegus in Previously Untreated Patients With Genotype 1 Chronic Hepatitis C

> **NCT01591460** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 165 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** boceprevir
- **DRUG:** peginterferon alfa-2a [Pegasys]
- **DRUG:** peginterferon alfa-2a [Pegasys]
- **DRUG:** ribavirin (Copegus]
- **DRUG:** ribavirin (Copegus]

## Key facts

- **NCT ID:** NCT01591460
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 165 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01591460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01591460, "A Triple Combination Therapy Study of Boceprevir, Pegasys and Copegus in Previously Untreated Patients With Genotype 1 Chronic Hepatitis C". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01591460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*